GMABGenmabRunning, no new patients
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
Diffuse Large B-Cell Lymphoma · Classic Follicular Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 184 (planned)
- Started
- Aug 17, 2022
- Main results expected
- Mar 2027
- Fully finished
- Mar 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Experiencing Grade 3 or Higher Cytokine Release Syndrome (CRS) Events
Measured over: Up to 3 Months
Percentage of Participants Experiencing Grade 3 or Higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events
Measured over: Up to 3 Months
Percentage of Participants Experiencing Grade 3 or Higher Neurotoxicity (Ntox) Events
Measured over: Up to 3 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05451810 · record last updated 2026-09-11 · checked 2026-11-09 15:47 UTC